Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Latest news

Read or download our press releases for all latest news about our company, research & development activities and updates for investors. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with Oxurion associates. Be sure to check in regularly for the latest Oxurion press releases or just subscribe to our mailing list to receive regular updates.

Subscribe to our mailing list

6 Apr 2021
Company; THR-149; THR-687; Investors
Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical...

31 Mar 2021
Investors; Company
OXURION to Participate in Upcoming Investor Meetings

Leuven, BE, Boston, MA, US – March 31st...

17 Mar 2021
Company; THR-149; THR-687; Investors
Oxurion NV Business and Financial Update – FY 2020

Advancing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies...

8 Mar 2021
Investors; Company
OXURION to Participate in Upcoming Investor Meetings

Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET –...

20 Jan 2021
Company
Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer

Leuven, BE and Boston, MA, US - January 20, 2021 – 08.00 AM CET –...

7 Jan 2021
Company; THR-149; THR-687; Investors
OXURION to Participate in Upcoming Investor Meetings

Leuven, BELGIUM, Boston, MA, US - January 7, 2021 – 08.00 AM CET –...

9 Nov 2020
THR-687
OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Leuven, Belgium and Boston, MA, November 9, 2020 – 7.30 AM CET –...

Archive

Media contact

Oxurion is committed and engaged to communicate openly with all of its stakeholders. For any media enquiries, comments or questions about Oxurion, please contact our Investor Relations & Corporate Communications team:

Wouter Piepers
Global Head of Corporate Communications and Investor Relations

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 16 751 310
Cell: +32 478 33 56 32
wouter.piepers@oxurion.com